AP-HP, Hôpital Saint-Antoine, service de médecine interne and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Sorbonne Universités, UPMC University Paris 06, F-75012 Paris, France.
Systemic Autoimmune Disease Unit, Department of Internal Medicine I, Vall d'Hebrón University Hospital, Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain.
Autoimmun Rev. 2017 Jul;16(7):730-734. doi: 10.1016/j.autrev.2017.05.006. Epub 2017 May 4.
To describe the consecutive pregnancy outcome and treatment in refractory obstetrical antiphospholipid syndrome (APS).
Retrospective multicenter open-labelled study from December 2015 to June 2016. We analyzed the outcome of pregnancies in patients with obstetrical APS (Sydney criteria) and previous adverse obstetrical event despite low-dose aspirin and low-molecular weight heparin LMWH (LMWH) conventional treatment who experienced at least one subsequent pregnancy.
Forty nine patients with median age 27years (23-32) were included from 8 European centers. Obstetrical APS was present in 71%, while 26% had obstetrical and thrombotic APS. Lupus anticoagulant was present in 76% and triple antiphospholipid antibody (APL) positivity in 45% of patients. Pregnancy loss was noted in 71% with a median age of gestation of 11 (8-21) weeks. The presence of APS non-criteria features (35% vs 17% in pregnancies without adverse obstetrical event; p=0.09), previous intrauterine death (65% vs 38%; p=0.06), of LA (90% vs 65%; p=0.05) were more frequent in pregnancies with adverse pregnancy outcome, whereas isolated recurrent miscarriage profile was more frequent in pregnancies without any adverse pregnancy outcome (15% vs 41%; p=0.04). In univariate analysis considering all pregnancies (index and subsequent ones), an history of previous intrauterine death was associated with pregnancy loss (odds-ratio 2.51 (95% CI 1.274.96); p=0.008), whereas previous history of prematurity related to APS (odds-ratio 0.13 95%CI 0.04 0.41, P=0.006), steroids use during the pregnancy (odds-ratio 0.30 95% CI 0.11-0.82, p=0.019) and anticardiolipids isolated profile (odds-ratio 0.51 95% CI 0.26-1.03, p=0.0588) were associated with favorable outcome. In multivariate analysis, only previous history of prematurity, steroids use and anticardiolipids isolated profiles were associated with live-birth pregnancy.
The main features of refractory obstetrical APS were the high rates of LA and triple APL positivity. Steroids could be effective in this APS profile, but prospective studies are necessary.
描述难治性产科抗磷脂综合征(APS)的连续妊娠结局和治疗方法。
这是一项 2015 年 12 月至 2016 年 6 月进行的回顾性多中心开放标签研究。我们分析了具有产科 APS(悉尼标准)且既往有不良产科病史的患者的妊娠结局,这些患者尽管接受了低剂量阿司匹林和低分子肝素(LMWH)常规治疗,但至少有一次后续妊娠。
来自 8 个欧洲中心的 49 名中位年龄为 27 岁(23-32 岁)的患者纳入本研究。71%的患者存在产科 APS,26%的患者存在产科和血栓性 APS。76%的患者存在狼疮抗凝物,45%的患者存在三抗磷脂抗体(APL)阳性。71%的患者发生妊娠丢失,中位孕龄为 11 周(8-21 周)。具有 APS 非标准特征(不良产科事件妊娠中 35% vs 17%;p=0.09)、既往宫内死亡(65% vs 38%;p=0.06)、LA 阳性(90% vs 65%;p=0.05)的患者妊娠丢失更常见,而无不良妊娠结局的患者中孤立性复发性流产的发生率更高(15% vs 41%;p=0.04)。在考虑所有妊娠(索引和后续妊娠)的单变量分析中,既往宫内死亡史与妊娠丢失相关(优势比 2.51(95%CI 1.274.96);p=0.008),而既往与 APS 相关的早产史(优势比 0.13(95%CI 0.04 0.41),P=0.006)、妊娠期间使用类固醇(优势比 0.30(95%CI 0.11-0.82),p=0.019)和孤立性抗心磷脂抗体阳性(优势比 0.51(95%CI 0.26-1.03),p=0.0588)与良好结局相关。多变量分析显示,只有既往早产史、类固醇使用和孤立性抗心磷脂抗体阳性与活产妊娠相关。
难治性产科 APS 的主要特征是 LA 和三抗磷脂抗体阳性率高。类固醇可能对此 APS 有效,但需要前瞻性研究。